Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Decreased by YHB Investment Advisors Inc.

YHB Investment Advisors Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 14.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,799 shares of the medical research company’s stock after selling 470 shares during the period. YHB Investment Advisors Inc.’s holdings in Edwards Lifesciences were worth $207,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of EW. Mount Yale Investment Advisors LLC grew its position in shares of Edwards Lifesciences by 1.9% in the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after acquiring an additional 162 shares in the last quarter. United Asset Strategies Inc. boosted its holdings in Edwards Lifesciences by 5.2% in the fourth quarter. United Asset Strategies Inc. now owns 168,159 shares of the medical research company’s stock worth $12,449,000 after purchasing an additional 8,242 shares during the period. Union Bancaire Privee UBP SA bought a new stake in Edwards Lifesciences during the fourth quarter valued at $1,120,000. Blue Trust Inc. raised its holdings in shares of Edwards Lifesciences by 35.6% during the fourth quarter. Blue Trust Inc. now owns 10,914 shares of the medical research company’s stock worth $808,000 after purchasing an additional 2,865 shares during the period. Finally, Crescent Grove Advisors LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth about $200,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock valued at $2,195,180 in the last quarter. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on EW shares. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Stifel Nicolaus boosted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, Robert W. Baird lowered their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Price Performance

NYSE:EW opened at $72.52 on Wednesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business’s 50-day moving average price is $72.32 and its 200 day moving average price is $70.19. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The firm has a market cap of $42.77 billion, a P/E ratio of 10.46, a PEG ratio of 3.54 and a beta of 1.11.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.